New drug for bone loss called Skelid (SKEL-id, tiludronate)

   Sanofi is launching a new drug for bone loss called Skelid (SKEL-id, tiludronate). It's a bisphosphonate...similar to Fosamax and Didronel (etidronate).

   Skelid is initially approved for Paget's disease. A three-month course works as well as six months of etidronate.

   But the real interest is in determining if Skelid is useful for osteoporosis...like Fosamax. We'll keep you posted.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote